Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.75 |
| ▸ | F2 | P00734 | 2/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3354082 | 1.00 | F10 (0.75) | F10F2ABCB11ST14 | |
| SCHEMBL79703 | 0.85 | F10 (0.87) | F10F2ABCB11ST14 | |
| SCHEMBL79715 | 0.81 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL76791 | 0.80 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL7247311 | 0.80 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL24177659 | 0.78 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL13698655 | 0.78 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL77589 | 0.78 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL77202 | 0.78 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL3521124 | 0.78 | F10 (1.00) | F10F2ABCB11ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120718-A1 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120718-A1 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | P2RY12, P2RY11, P2RY1 | F10 1174/4885F2 398/4885ABCB11 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.